Compare PTRN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTRN | TVTX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.3B |
| IPO Year | 2025 | 2013 |
| Metric | PTRN | TVTX |
|---|---|---|
| Price | $20.67 | $63.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $19.56 | ★ $40.62 |
| AVG Volume (30 Days) | ★ 1.7M | 1.6M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $2,501,315,000.00 | N/A |
| Revenue This Year | $27.89 | $44.76 |
| Revenue Next Year | $22.19 | $35.51 |
| P/E Ratio | $69.16 | ★ N/A |
| Revenue Growth | ★ 39.26 | N/A |
| 52 Week Low | $9.19 | $17.05 |
| 52 Week High | $29.80 | $66.24 |
| Indicator | PTRN | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.21 | 65.04 |
| Support Level | $19.50 | $53.76 |
| Resistance Level | $25.85 | $66.24 |
| Average True Range (ATR) | 1.49 | 2.56 |
| MACD | -0.28 | 0.30 |
| Stochastic Oscillator | 22.05 | 75.27 |
Pattern Group Inc is an e-commerce accelerator that uses its technology platform, data science, and a team of experts to drive growth for brands. The Company acquires inventory from brand partners to sell to consumers, enabling full control over content, pricing, logistics, and customer service. Brand partners that contract with the Company operate in various industries, including health and wellness, beauty and personal care, home and lifestyle, pet, sports and outdoors, and consumer electronics. The Company mainly derives its revenue in the United States by selling products to customers via online marketplaces. The company genrates majority of revenue from the US.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.